Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Added: 3 days ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview… View more
Author(s): Vasvi Singh Added: 2 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights… View more
Author(s): Added: 2 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly… View more
Author(s): Sven Plein , , Added: 1 year ago
This breakout session – first broadcast as part of the inaugural New Horizons in Amyloidosis (NHA) meeting, held in February 2024 – is moderated by Dr Timothy Albert (Circle Cardiovascular Imaging), with faculty Dr Kanae Mukai (Salinas Valley Health, US) and Dr Sven Plein (University of Leeds, UK).The session provides insight into the clinical integration of cardiac MRI, supported by practical,… View more
Author(s): Harriette Van Spall , Udo Bavendiek Added: 2 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study… View more
Author(s): Brian Lindman Added: 7 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more
Author(s): Marianna Fontana Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more